Logo

Correction: Feb 4, 2005

Feb 04, 2005
Premium

RNAi News incorrectly reported last week that CytRx CEO Steven Kriegsman had stated than an investigational new drug application for an siRNA-based amyotrophic lateral sclerosis treatment is expected to be filed in the second half of 2005.

Although the company’s earlier goal of filing an IND before the end of 2004 was dropped, a new timeline has not been established.

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.